Navigation Links
Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
Date:9/30/2010

ed changes in the size of our markets, our market share and product sales and other statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of our clinical trials; our ability to develop and commercialize products; our ability to obtain required regulatory approvals; the success of current and future collaborative relationships; the market acceptance of our products; our ability to compete with larger, better financed pharmaceutical and biotechnology companies; new approaches to the treatment of our targeted diseases; our expectation of incurring continued losses; our uncertainty of product revenues and profits; our ability to generate future revenues; our ability to raise additional capital to continue our drug development programs; our compliance with all Food and Drug Administration regulations; our ability to obtain; maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales and manufacturing capabilities; our dependence on third-party manufacturers and value added resellers; our ability to hire and retain skilled personnel; our volatile stock price; and other risks detailed in Repligen's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management's current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in it
'/>"/>
SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
2. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
3. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
4. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
5. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
6. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
7. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
8. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
9. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
10. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
11. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind alle ... SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 ... besuchen. Diese Tagung soll dazu ... Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, die ...
(Date:12/15/2014)... 12, 2014 Research and Markets ( ... "Inferior Vena Cava (IVC) Filters - Global Trends, Estimates ... http://photos.prnewswire.com/prnh/20130307/600769 Global ... reach US$435 million by 2016. The North ... the global value while Europe ...
(Date:12/15/2014)... and HERZLIYA PITUACH, Israel , Dec. ... IMNP ) announced today that its Board of ... succeeding Dr. Daniel Teper who continues as Chief ... of Immune,s Board of Directors since 2013. Immune,s ... delighted to represent the interest of shareholders and to continue ...
Breaking Medicine Technology:Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ... to the pivotal Phase II trial of its lead ... novo poor-risk acute myelogenous leukemia (AML). Alan Kessman, ... reached this milestone in the pivotal Phase II trial ...
... Study to Explore the Efficacy of Novel Proteasome Inhibitor ... Patients with Relapsed and Refractory Multiple Myeloma, SOUTH ... Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today,announced ... Phase 2,clinical trial to study Proteolix,s potent and selective ...
Cached Medicine Technology:Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 2Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 4The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a ... Future” and co-founder of the Ace Medical Weight Loss Center ... a broad look at the industry of weight loss, and ... On film and in television shows, however, she says the ... aspects and played for basic laughs, which she believes impacts ...
(Date:12/17/2014)... 2014 This prestigious award is ... have made outstanding and innovative contributions to the ... of private practice physical therapy by the Private ... , On behalf of Performance Physical Therapy, Michelle ... of Performance accepted the award at the Private ...
(Date:12/17/2014)... A group of 127 scientists sent an ... reaction to a recent statement by the center that was ... derogated the efficacy of all brain exercises. , Signatories to ... of the center’s statement critical of brain exercise companies that ... overstated its case, in a document it had entitled “A ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
(Date:12/17/2014)... Project Veritas is releasing a video interview ... economist and Obamacare architect Jonathan Gruber to public attention. ... interview, which is being distributed on YouTube. , During ... in the Affordable Care Act in order to hide ... dollar per year tax grab. , “President Obama promised ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
... , , Central and western region facilities ... , , HARRISBURG, Pa., June 4 Over 300 ... healthcare-associated infections (HAIs) this week to the Patient Safety Authority ... western regions of the state will begin reporting by the ...
... and Technologist Symposium at TCT 2009 will examine the ... the management of the cardiovascular patient: ... decisions, Management decisions regarding patients with drug-eluting stents, Leadership, ... own health WHEN: September 21-22, 2009 ...
... available in French . , Montreal, June ... pulmonary disease, is a disease that results in severe breathing ... fourth leading killer worldwide. However the mechanisms responsible for some ... been well understood. Dr.Manuel Cosio from the McGill ...
... Recovery & Reinvestment Act, Electronic Health Records (EHR) implementation and ... Systems Corporation (NYSE: PER ) ( www.perotsystems.com ... "The Impact of The U.S. Stimulus on Healthcare IT," that ... industry. , , To access this video, please click ...
... Alaska Governor Sarah Palin, named "2009 Honoree" by the ... ), will be honored before a sold out crowd of ... on Sunday, June 7(th) at Flowerfields in St. James. , ... Long Island. Independent Group Home Living (IGHL; ...
... Ohio Children,s Hospital Association (OCHA) and its six ... Hospital Medical Center; Dayton Children,s Medical Center; Nationwide ... Cleveland; and Toledo Children,s Hospital - today released ... quality in children,s hospitals. , , OCHA ...
Cached Medicine News:Health News:Over 300 Pennsylvania Nursing Homes in Eastern Pennsylvania Begin Reporting Healthcare-Associated Infections 2Health News:Nurses: Providing angioplasty patient care in and out of the cath lab 2Health News:Investigation finds that cigarette smoking does not affect everyone in same way 2Health News:Perot Systems Releases ARRA Webcast Featuring Leading Analyst Firm 2Health News:Perot Systems Releases ARRA Webcast Featuring Leading Analyst Firm 3Health News:Alaska Governor Sarah Palin to be Honored Before Sold Out Crowd at IGHL 30(th) Anniversary Gala During First Visit to Long Island 2Health News:Ohio's Children's Hospitals Release New Results of Collaboration Aimed at Saving Children's Lives 2Health News:Ohio's Children's Hospitals Release New Results of Collaboration Aimed at Saving Children's Lives 3
... distinctive COLOR PURPLE* distinguish SAFESKIN* PURPLE ... sterile clinical procedures when an exceptionally ... designed as an alternative for individuals ... hypersensitivity to natural rubber latex proteins. ...
... Intraoperative Leg Positioner frees the OR staff to ... 2nd assistants to hold the leg, while enabling ... instead of leg positioning. The Siegel MAST Leg ... in any position required for knee surgery and ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Color: ...
... compact design makes this pipette useful ... ammonia in urine, and blood serum ... Deliver" by blowing out the last ... Color: orange Measur range: volume 2.0 ...
Medicine Products: